Product Description
Lacripep, which is derived from the Lacritin protein, is a first-in-class topical therapy that preserves all of Lacritin's bioactivity. (Sourced from: https://tearsolutions.com)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Ophthalmic
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: TearSolutions, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Keratoconjunctivitis Sicca|Sjogren's Syndrome|Dry Eye Syndromes|Corneal Injuries
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06854393 |
WRNMMC-2024-0470 | P2 |
Recruiting |
Corneal Injuries |
2027-06-01 |
12% |
2025-07-04 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT03226444 |
LOS-001 | P2 |
Completed |
Sjogren's Syndrome|Keratoconjunctivitis Sicca|Dry Eye Syndromes |
2019-12-27 |
67% |
2020-01-28 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |